跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/jRCT2031200247
jRCT2031200247进行中（未招募）不适用

A PHASE 1 OPEN-LABEL STUDY OF HER3-DXd (PATRITUMAB DERUXTECAN; U3-1402) IN COMBINATION WITH OSIMERTINIB IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)

Daiichi Sankyo Co., Ltd.0 个研究点目标入组 280 人开始时间: 2020年12月21日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
280
主要终点
Objective Response Rate (ORR)
研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 No limit（—）
性别
All

入选标准

  • •Inclusion Criteria Specific to Dose Escalation and Second-Line Dose Expansion:
  • •Documentation of EGFR exon 19 deletion or L858R mutation detected from tumor tissue
  • •Must have received osimertinib for locally advanced or metastatic disease at a dose of 80 mg QD for at least 6 weeks and must not miss more than two doses during the 2 weeks prior to the first day of study treatment (Cycle 1, Day 1)
  • •Must not have received any other prior systemic cancer therapies in the locally advanced/metastatic setting
  • •Has documentation of radiological disease progression following first-line treatment with osimertinib in the locally advanced or metastatic setting
  • •Inclusion Criteria Specific to First-Line Dose Expansion:
  • •The tumor tissue harbors one of the 2 common EGFR mutations occurring in NSCLC known to be associated with EGFR-TKI sensitivity (exon 19 deletion or L858R) as assessed by Clinical Laboratory Improvement Amendments (CLIA)-certified (US sites), accredited (outside of the US), local laboratory or central laboratory. Only tissue-basedtesting will be accepted.
  • •Subjects must have previously untreated locally advanced or metastatic NSCLC and must be eligible to receive first-line treatment with osimertinib, according to the judgment of the investigator. Prior adjuvant or neo-adjuvant therapy (chemotherapy, radiotherapy, investigational agents; except with osimertinib) is permitted.
  • •Common Inclusion Criteria For All Subjects:
  • •Male or female subjects aged >=18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
  • •Has locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation
  • •At least 1 measurable lesion as assessed by investigator assessment according to RECIST v1.1
  • •Tissue requirements
  • •a. Dose Escalation (all cohorts): provide an optional pre-treatment tumor tissue of sufficient quantity, as defined in the laboratory manual. The optional pre-treatment tumor tissue can be provided as either:
  • •Pre-treatment tumor biopsy from at least 1 lesion not previously irradiated and amenable to core biopsy.
  • •Archival tissue collected from a biopsy performed prior to signing of the tissue consent, and since progression while on treatment with the most recent cancer therapy regimen.
  • •b. First-line Dose Expansion (Cohorts 3, 4a, and 4b): provide an optional pre-treatment and optional on-treatment tumor tissues of sufficient quantity, as defined in the laboratory manual. The optional pre-treatment tumor tissue can be provided as either:
  • •Pre-treatment tumor biopsy from at least 1 lesion not previously irradiated and amenable to core biopsy.
  • •Archival tissue collected from a biopsy performed at the time of the initial diagnosis or later
  • •c. Second-line Dose Expansion (Arm 1, Arm 1b, and Arm 2): provide a required pre-treatment and required on-treatment tumor tissues of sufficient quantity, as defined in the laboratory manual. The required pre-treatment tumor tissue can be provided as either:
  • •Pre-treatment tumor biopsy from at least 1 lesion not previously irradiated and amenable to core biopsy.
  • •Archival tissue collected from a biopsy performed prior to signing of the tissue consent, and since progression while on treatment with the most recent cancer therapy regimen
  • •Has adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1 defined as:
  • •Platelet count: >=100 000/mm^3 or >=100 x 10^9/L (platelet transfusions are not allowed within 14 days prior to the assessment of platelets during the screening period in order to meet the study inclusion criterion)
  • •Hemoglobin: >=9.0 g/dL (transfusion of red blood cells and/or growth factor support is not allowed within 14 days prior to the assessment of hemoglobin during the screening period in order to meet the study inclusion criterion)
  • •Absolute neutrophil count (ANC): >=1500/mm^3 or >=1.5 x 10^9/L (granulocyte colony stimulating factor support is not allowed within 14 days prior to the assessment of ANC during the screening period in order to meet the study inclusion criterion)
  • •Creatinine clearance (CrCl): CrCl >=30 mL/min as calculated using the Cockcroft-Gault equation or measured CrCl
  • •Aspartate aminotransferase/alanine aminotransferase: <=3 x ULN (if liver metastases are present, <=5 x ULN)
  • •Total bilirubin: <=1.5 x ULN if no liver metastases (<3 x ULN in the presence of documented Gilbert`s syndrome [unconjugated hyperbilirubinemia] or liver metastases)
  • •Serum albumin: >=2.5 g/dL
  • •Alkaline phosphatase (ALP) and Gamma-glutamyl transferase (GGT): <=2.5 x ULN of both ALP and GGT
  • •Prothrombin time or prothrombin time-international normalized ratio and activated partial thromboplastin time/ partial thromboplastin time: <=1.5 x ULN, except for subjects on coumarin-derivative anticoagulants or other similar anticoagulant therapy, who must have prothrombin time-international normalized ratio within therapeutic range as deemed appropriate by the Investigator

排除标准

  • •Any previously documented histologic or cytologic evidence of small cell OR combined small cell/non small cell disease
  • •Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroid therapy, has current ILD, or is suspected to have such disease by imaging during screening.
  • •Clinically severe pulmonary compromise (based on Investigator`s assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:
  • •a. any underlying pulmonary disorder (eg, pulmonary emboli within three months of the study enrollment or randamization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, or pleural effusion)
  • •b. any autoimmune, connective tissue or inflammatory disorder with pulmonary
  • •involvement (eg, rheumatoid arthritis, Sjogren's syndrome, or sarcoidosis)
  • •OR prior complete pneumonectomy
  • •Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1, Day
  • •Subjects who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
  • •Evidence of any leptomeningeal disease
  • •Has spinal cord compression or clinically active central nervous system metastases, defined as symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases who are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study, but must have a stable neurologic status for at least 4 weeks prior to Cycle 1, Day
  • •Subjects with asymptomatic brain metastases and treated with anticonvulsants as prophylaxis are able to enroll following a 14-day washout period. Note: A CT or MRI scan of the brain at baseline is required for all subjects.
  • •Inadequate washout period prior to Cycle 1, Day 1 (Dose Escalation and First-Line Dose Expansion) or prior to randomization (Second-Line Dose Expansion) defined as:
  • •a. Whole brain radiation therapy <28 days or stereotactic brain radiation therapy <7 days
  • •b. Any systemic anticancer (excluding osimertinib in all Dose Escalation cohorts and in Second-Line Dose Expansion [Arms 1, 2, and 1b]), including investigational agents, <14 days or 5 half-lives, whichever is longer
  • •c. Immune checkpoint inhibitor therapy <=21 days
  • •d. Major surgery (excluding placement of vascular access) <4 weeks
  • •e. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation < 28 days or palliative radiation therapy <7 days
  • •f. Chloroquine or hydroxychloroquine <=14 days
  • •g. Medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4 < 21 days.
  • •Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, Grade <=1 or baseline. Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee.
  • •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow osimertinib, or previous significant bowel resection that would preclude adequate absorption of osimertinib
  • •Has any primary malignancy other than locally advanced or metastatic NSCLC within 3 years prior to Cycle 1, Day 1, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated
  • •Uncontrolled or significant cardiovascular disease prior to Cycle 1, Day 1, including:
  • •a. Mean corrected QT interval using Fridericia's formula (QTcF) interval of >450 ms in 3 successive central screening measurements
  • •b. Left ventricular ejection fraction (LVEF) <=45% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan
  • •c. Resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg)
  • •d. Myocardial infarction within 6 months
  • •e. New York Heart Association (NYHA) Classes 3 or 4 congestive heart failure within 28 days
  • •f. Uncontrolled angina pectoris within 6 months
  • •g. Has cardiac arrhythmia requiring antiarrhythmic treatment
  • •h. Complete left or right bundle branch block within 6 months
  • •i. History of second- or third-degree heart block or PR interval >250 ms within 6 months
  • •j. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes
  • •k. Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval
  • •Has clinically significant corneal disease.
  • •Any evidence of severe or uncontrolled diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the Investigator`s opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
  • •Has a known human immunodeficiency virus (HIV) infection that is not well controlled.

结局指标

主要结局

Objective Response Rate (ORR)

As Assessed by Blinded Independent Central Review(BICR) Based on RECIST v1.1

次要结局

  • DoR
  • DCR
  • TTR
  • PFS
  • OS
  • CBR

研究者

相似试验

招募中
1 期
HER3-DXd (Patritumab Deruxtecan ; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerMetastatic or Locally Advanced Non-Small Cell Lung Cancer
JPRN-jRCT2031200247Inoguchi Akihiro280
招募中
2 期
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTNon-Small Cell Lung CarcinomaAdvanced Non-Small Cell Squamous Lung CancerEGFR Gene Mutation
NCT06222489The Netherlands Cancer Institute16
招募中
不适用
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors (HERTHENA-PanTumor01)
jRCT2031230575Daiichi Sankyo Co., Ltd.400
尚未招募
不适用
HER3-DXd with Other Anticancer Agents in HER2+ Unresectable Locally Advanced BC or mBC
jRCT2041250022MSD K.K.3
撤回
2 期
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain MetastasesBrain Metastases, Adult
NCT05620914Mustafa Khasraw, MBChB, MD, FRCP, FRACP15